MolEcular Taxonomy of BReast cancer International Consortium (METABRIC)
|
|
- Darren Chambers
- 6 years ago
- Views:
Transcription
1 PERSPECTIVE 1
2 LARGE SCALE DATASET EXAMPLES MolEcular Taxonomy of BReast cancer International Consortium (METABRIC) BC Cancer Agency, Vancouver Samuel Aparicio, PhD FRCPath Nan and Lorraine Robertson Chair of Breast Cancer Research BC Cancer Agency, Vancouver /UBC 2
3 People Cambridge Carlos Caldas (PI); Chris5na Cur5s (lead bioinforma5cian); James Brenton (Co- PI); Irene Papatheodorou (database bioinforma5cian) Vancouver Sam Aparicio (PI); Sohrab Shah (lead bioinforma5cian) Manitoba Canada (Lee Murphy, Co- PI) Guys UK (Arnie Purushotham, Co- PI) NoJngham (Ian Ellis) 3
4 METABRIC (MolEcular Taxonomy of BReast cancer Interna5onal Consor5um) 5 Centres, 2 Canadian, 3 UK Vancouver (Sam Aparicio), Manitoba Cambridge (Carlos Caldas), NoJngham, Guys Develop a robust mul5- modality molecular prognos5c classifica5on of breast cancer Establish a platorm of resources for future valida5on studies. Target discovery in 2000 frozen breast cancers annotated with 10 year outcomes 4
5 HOW MANY DISEASES MAKE UP BREAST CANCER? ~65% ER+ ER- ~35% HER2- ER+ ~15 % HER2+ trastuzumab HER2- ER- Express Basal markers Non basal Low mitotic rate High mitotic rate Special types (usually low mitotic rate) LOBULAR, TUBULAR Heterogenous group Younger patients Fewer therapeutic options Endocrine therapy +/- cytotoxic chemo 5
6 Breast cancer is heterogeneous and we cannot fully explain the variation (Caldas & Aparicio, Nature 2002) 6
7 HOW MANY DISEASES IS BREAST CANCER? LUMINAL - ER+, PR+, HER2 nonamp TRIPLE NEGATIVE (HER2 non amp, ER-, PR-) HER2+, LUMINAL (ER+) HER2+, ER-, PR- (Cheang et al Clin. Cancer Res 2008) 7
8 Clinical and biological ques5ons being addressed by METABRIC Can a good prognosis group of women with node- nega3ve disease at very low risk of relapse be clearly iden5fied, (and hence for whom the risk- benefit ra5o might be in favour of withholding chemotherapy)? Can women with aggressive disease at risk of local or distance relapse be more clearly iden5fied? Can surrogate molecular markers of nodal status be developed? What are the underlying molecular drivers of the subtypes? 8
9 Frustra5ons that led to METABRIC The expression datasets are too small (a few hundred pa5ents at most) to fully represent the breast cancer subtypes The current expression sets have been measured on different platorms different probesets/platorm variance Highly curated long term clinical outcomes data is missing on most Fixed expression changes driven by copy number have not been systema5cally mapped Mapping of muta5on space not done 9
10 METABRIC core dataset SNP6.0 and Illumina arrays in > 2100 breast cancers with > 5yrs clinical follow up 1000 node - ve, no systemic therapy 500 node +ve, ER+ve, hormone therapy alone 500 node +ve, ER- ve, with systemic therapy 450 matched normals Mul5point high resolu5on genomic analysis High density acgh Expression profiling including alterna5ve splicing microrna/epigenomic analysis Resequencing of hostpot genes (p53, PIK3CA) in 2000 cases PlaTorm resources (amplified DNA, RNA, TMA) microrna expression (in progress) Whole genome next gen sequencing of a subset 10
11 Augmented HMM distinguishes CNVs from somatic changes
12 Segmental copy number instability dominates the landscape in breast cancers IGF1R ERBB2 ESR1 FRS2 DUSP6 RASSF9 12
13 Small subgroups become apparent with cases EGFR (7p12) IGF1R (15q26) K-Ras (12p12) Mir21 (7q21) 13
14 Homozygous dele5ons form part of the landscape PTEN BRCA2 CDKN2A UTX 14
15 Approximately 30% of genes have cis-acting copy number induced expression HER2 locus:
16 The era of cancer genome sequencing is upon us how should we traverse the landscape? 16
17 Individual breast cancer patients have multiple diseases mutational heterogeneity lymphocytes Supporting normal cells Malignant cells +/- mutations primary 5 somatic mutations were present at dominant frequencies in the primary: PALB2, HAUS3, SLC24A4, ABCG11, SNX4 mutations 9 YEAR INTERVAL recurrence 6 somatic mutations were present at low frequencies (1-13%) in the primary: KIF1C, USP28, MYH8, MORC1, KIAA1468, RNASEH2A The rest ie. 19 of 32 somatic coding nonsynonymous mutations, were not detectable in the primary tumour cell population 17
18 Challenges for the network modeling We have disparate data types con5nuous expression measurements & discrete types The genome aberra5on data have a sparse distribu5on There is intra- tumoural heterogeneity 18
19 Ongoing work Genome sequencing of 200 triple nega5ve breast cancers incorpora5ng revised copy number/ expression classifica5on. Clinical trials associated sequencing of tumours. (PARP) Profiling of drug resistance by sequencing and genome wide sirna screens 19
The clonal and mutational spectrum of marker negative breast cancers (TNBC)
The clonal and mutational spectrum of marker negative breast cancers (TNBC) Samuel AJR Aparicio BM BCh PhD FRCPath Nan and Lorraine Robertson Chair, UBC Canada Research Chair, Molecular Oncology BC Cancer
More informationGenomic tests to personalize therapy of metastatic breast cancers. Fabrice ANDRE Gustave Roussy Villejuif, France
Genomic tests to personalize therapy of metastatic breast cancers Fabrice ANDRE Gustave Roussy Villejuif, France Future application of genomics: Understand the biology at the individual scale Patients
More informationContemporary Classification of Breast Cancer
Contemporary Classification of Breast Cancer Laura C. Collins, M.D. Vice Chair of Anatomic Pathology Professor of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Outline
More informationRecent advances in breast cancers
Recent advances in breast cancers Breast cancer is a hetrogenous disease due to distinct genetic alterations. Similar morphological subtypes show variation in clinical behaviour especially in response
More informationCharacterisation of structural variation in breast. cancer genomes using paired-end sequencing on. the Illumina Genome Analyser
Characterisation of structural variation in breast cancer genomes using paired-end sequencing on the Illumina Genome Analyser Phil Stephens Cancer Genome Project Why is it important to study cancer? Why
More informationFISH mcgh Karyotyping ISH RT-PCR. Expression arrays RNA. Tissue microarrays Protein arrays MS. Protein IHC
Classification of Breast Cancer in the Molecular Era Susan J. Done University Health Network, Toronto Why classify? Prognosis Prediction of response to therapy Pathogenesis Invasive breast cancer can have
More informationFrom pathology research to stratified medicine trials
From pathology research to stratified medicine trials Dr. John Bartlett Program Director Transformative Pathology C CCTG Breast Group Steering Committee ASCO-CAP HER2 Panel As is your Pathology, so is
More informationTriple Negative Breast Cancer
Triple Negative Breast Cancer Prof. Dr. Pornchai O-charoenrat Division of Head-Neck & Breast Surgery Department of Surgery Faculty of Medicine Siriraj Hospital Breast Cancer Classification Traditional
More informationSYSTEMIC THERAPY OPTIONS FOR BREAST CANCER IN 2014
SYSTEMIC THERAPY OPTIONS FOR BREAST Oncology Day 2014 CANCER IN 2014 Dr. Katherine Enright, M.D., M.P.H., F.R.C.P.(C) Katherine.enright@Trilliumhealthpartners.ca OBJECTIVES 1. Outline an approach to the
More informationTriple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008
Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008 Triple Negative Breast Cancer 15% 25% Triple Negative 20% HER2+ ER+ Low Grade
More informationMaram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine
Maram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine The most common non-skin malignancy of women 2 nd most common cause of cancer deaths in women, following
More informationComprehensive Genomic Profiling, in record time. Accurate. Clinically Proven. Fast.
Comprehensive Genomic Profiling, in record time Accurate. ly Proven. Fast. PCDx advantages Comprehensive genomic profiling, in record time PCDx Comprehensive Genomic Profiling (CGP) provides precise information
More informationMolecular classification of breast cancer implications for pathologists. Sarah E Pinder
Molecular classification of breast cancer implications for pathologists Sarah E Pinder Courtesy of CW Elston Histological types Breast Cancer Special Types 17 morphological special types 25-30% of all
More informationUK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin
UK Interdisciplinary Breast Cancer Symposium Should lobular phenotype be considered when deciding treatment? Michael J Kerin Professor of Surgery National University of Ireland, Galway and Galway University
More informationHEALTH CARE DISPARITIES. Bhuvana Ramaswamy MD MRCP The Ohio State University Comprehensive Cancer Center
HEALTH CARE DISPARITIES Bhuvana Ramaswamy MD MRCP The Ohio State University Comprehensive Cancer Center Goals Understand the epidemiology of breast cancer Understand the broad management of breast cancer
More informationCarcinoma mammario triple nega0ve Nuove acquisizioni biologiche. Giuseppe Curigliano MD PhD UNIMI & IEO
Carcinoma mammario triple nega0ve Nuove acquisizioni biologiche Giuseppe Curigliano MD PhD UNIMI & IEO Outline San Antonio Breast Cancer Symposium, December 5-9, 2017 The year of DNA Repair targe?ng Olaparib
More informationComputer Science, Biology, and Biomedical Informatics (CoSBBI) Outline. Molecular Biology of Cancer AND. Goals/Expectations. David Boone 7/1/2015
Goals/Expectations Computer Science, Biology, and Biomedical (CoSBBI) We want to excite you about the world of computer science, biology, and biomedical informatics. Experience what it is like to be a
More informationNational Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant
National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant Reporting Period July 1, 2011 June 30, 2012 Formula Grant Overview The National Surgical
More informationBreast Cancer Statistics
1 in 8 Breast Cancer Statistics Incidence Mortality Prevalence 2 Breast Cancer Incidence Breast Cancer Mortality Breast Cancer Prevalence ~$100,000 Female Breast Anatomy Breasts consist mainly of fatty
More informationBasement membrane in lobule.
Bahram Memar, MD Basement membrane in lobule. Normal lobule-luteal phase Normal lobule-follicular phase Lactating breast Greater than 95% are adenocarcinomas in situ carcinomas and invasive carcinomas.
More informationUnderstanding and Optimizing Treatment of Triple Negative Breast Cancer
Understanding and Optimizing Treatment of Triple Negative Breast Cancer Edith Peterson Mitchell, MD, FACP Clinical Professor of Medicine and Medical Oncology Program Leader, Gastrointestinal Oncology Department
More informationWhole Genome and Transcriptome Analysis of Anaplastic Meningioma. Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute
Whole Genome and Transcriptome Analysis of Anaplastic Meningioma Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute Outline Anaplastic meningioma compared to other cancers Whole genomes
More informationHistological Type. Morphological and Molecular Typing of breast Cancer. Nottingham Tenovus Primary Breast Cancer Study. Survival (%) Ian Ellis
Morphological and Molecular Typing of breast Cancer Ian Ellis Molecular Medical Sciences, University of Nottingham Department of Histopathology, Nottingham University Hospitals NHS Trust Histological Type
More informationBreast Cancer. Excess Estrogen Exposure. Alcohol use + Pytoestrogens? Abortion. Infertility treatment?
Breast Cancer Breast Cancer Excess Estrogen Exposure Nulliparity or late pregnancy + Early menarche + Late menopause + Cystic ovarian disease + External estrogens exposure + Breast Cancer Excess Estrogen
More information2017 Breast Cancer Update
2017 Breast Cancer Update Alberto J Montero, M.D., MBA Quality Improvement Officer, Taussig Cancer Institute, Lerner College of Medicine Cleveland Clinic N/A Disclosure Overview Epidemiology (US/Global)
More informationPredictive Assays in Radiation Therapy
Outline Predictive Assays in Radiation Therapy Radiation Biology Introduction Early predictive assays Recent trends in predictive assays Examples for specific tumors Summary Lecture 4-23-2014 Introduction
More informationOUTLINE PAST PRESENTFUTURE BREAST CANCER INCIDENCE AND MORTALITY CURRENT STATE OF MEDICAL ONCOLOGY SECOND ANNUAL BREAST CANCER SYMPOSIUM
OUTLINE CURRENT STATE OF MEDICAL ONCOLOGY SECOND ANNUAL BREAST CANCER SYMPOSIUM October 11, 2014 SARA M GARRIDO, M.D., F.A.C.P Chief Medical Officer at AMS Miami, October 11, 2014 PAST PRESENTFUTURE -BRIEF
More informationImmunohistochemical classification of breast tumours
Immunohistochemical classification of breast tumours Workshop in Diagnostic Immunohistochemistry September 19 th - 21 th 2018 Anne-Vibeke Lænkholm Department of Surgical Pathology, Zealand University Hospital,
More informationComputational Investigation of Homologous Recombination DNA Repair Deficiency in Sporadic Breast Cancer
University of Massachusetts Medical School escholarship@umms Open Access Articles Open Access Publications by UMMS Authors 11-16-2017 Computational Investigation of Homologous Recombination DNA Repair
More informationGene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA
Gene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA When Are Biomarkers Ready To Use? Same Rules for Gene Expression Panels Key elements
More information10/15/2012. Inflammatory Breast Cancer vs. LABC: Different Biology yet Subtypes Exist
Triple-Negative Breast Cancer: Optimizing Treatment for Locally Advanced Breast Cancer Beth Overmoyer MD Director, Inflammatory Breast Cancer Program Dana Farber Cancer Institute Overview Inflammatory
More informationpatients in the era of
Communicating with cancer patients in the era of personalized medicine September 9 th, 2017 Gerald Prager, M.D. Comprehensive Cancer Center Vienna Medical University of Vienna, Austria Gerald Prager, M.D.
More informationGenetic alterations of histone lysine methyltransferases and their significance in breast cancer
Genetic alterations of histone lysine methyltransferases and their significance in breast cancer Supplementary Materials and Methods Phylogenetic tree of the HMT superfamily The phylogeny outlined in the
More informationBreast Cancer Basics. Clinical Oncology for Public Health Professionals. Ben Ho Park, MD, PhD
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationRTWG - Carcinosarcoma. Max Parmar, Jane Bryce, Andreas Poveda, Amit Oza
RTWG - Carcinosarcoma Max Parmar, Jane Bryce, Andreas Poveda, Amit Oza Overview Background Questions urgent and timely investigations? Proposed Approach Regulatory Solutions Output Carcinosarcomas Background
More informationSummary BREAST CANCER - Early Stage Breast Cancer... 3
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 BREAST CANCER - Early Stage Breast Cancer... 3 Large data analysis reveals similar survival outcomes with sequential
More informationAnalysis of Massively Parallel Sequencing Data Application of Illumina Sequencing to the Genetics of Human Cancers
Analysis of Massively Parallel Sequencing Data Application of Illumina Sequencing to the Genetics of Human Cancers Gordon Blackshields Senior Bioinformatician Source BioScience 1 To Cancer Genetics Studies
More informationIntro to Cancer Therapeutics
An Intro to Cancer Therapeutics Christopher R. Chitambar, MD Professor of Medicine Division of Hematology & Oncology Froedtert and Medical College of Wisconsin Clinical Cancer Center cchitamb@mcw.edu Intro
More informationClasificación Molecular del Cáncer de Próstata. JM Piulats
Clasificación Molecular del Cáncer de Próstata JM Piulats Introduction The Gleason score is the major method for prostate cancer tissue grading and the most important prognostic factor in this disease.
More informationBiologic Subtypes and Prognos5c Factors. Claudine Isaacs, MD Georgetown University
Biologic Subtypes and Prognos5c Factors Claudine Isaacs, MD Georgetown University Prognos5c Factor Defini5on Predicts outcome in absence of systemic therapy Thus tell us when (not how) to treat a pa5ent
More informationNational Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2011 Formula Grant
National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2011 Formula Grant Reporting Period July 1, 2012 June 30, 2013 Formula Grant Overview The NSABP Foundation
More informationARTICLE RESEARCH. Macmillan Publishers Limited. All rights reserved
Extended Data Figure 6 Annotation of drivers based on clinical characteristics and co-occurrence patterns. a, Putative drivers affecting greater than 10 patients were assessed for enrichment in IGHV mutated
More informationJ Clin Oncol 24: by American Society of Clinical Oncology INTRODUCTION
VOLUME 24 NUMBER 36 DECEMBER 20 2006 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer
More informationMorphological and Molecular Typing of breast Cancer
Morphological and Molecular Typing of breast Cancer Ian Ellis Molecular Medical Sciences, University of Nottingham Department of Histopathology, Nottingham University Hospitals NHS Trust Histological
More informationRole of Genomic Profiling in (Minimally) Node Positive Breast Cancer
Role of Genomic Profiling in (Minimally) Node Positive Breast Cancer Kathy S. Albain, MD, FACP Professor of Medicine Dean s Scholar Loyola University Chicago Stritch School of Medicine Cardinal Bernardin
More informationMolecular Characterization of Breast Cancer: The Clinical Significance
Molecular Characterization of : The Clinical Significance Shahla Masood, M.D. Professor and Chair Department of Pathology and Laboratory Medicine University of Florida College of Medicine-Jacksonville
More informationBreast cancer: Molecular STAGING classification and testing. Korourian A : AP,CP ; MD,PHD(Molecular medicine)
Breast cancer: Molecular STAGING classification and testing Korourian A : AP,CP ; MD,PHD(Molecular medicine) Breast Cancer Theory: Halsted Operative breast cancer is a local-regional disease The positive
More informationModern classification of breast cancer-should we stick with morphology or convert to molecular profiles?
Modern classification of breast cancer-should we stick with morphology or convert to molecular profiles? Ian Ellis Professor of Cancer Pathology Molecular Medical Sciences University of Nottingham Dept
More informationSupplementary Data for:
Supplementary Data for: Tumour sampling method can significantly influence gene expression profiles derived from neoadjuvant window studies Dominic A. Pearce 1, Laura M. Arthur 1, Arran K. Turnbull 1,
More informationChapter 5: Epidemiology of MBC Challenges with Population-Based Statistics
Chapter 5: Epidemiology of MBC Challenges with Population-Based Statistics Musa Mayer 1 1 AdvancedBC.org, Abstract To advocate most effectively for a population of patients, they must be accurately described
More informationTNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017
TNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017 The problem with TNBC 1. Generally more aggressive 2. ONLY chemotherapy 3. No other
More informationTriple-Negative Breast Cancer Time to Slice and Dice? Carsten Denkert, MD Charité University Hospital Berlin, Germany
Triple-Negative Breast Cancer Time to Slice and Dice? Carsten Denkert, MD Charité University Hospital Berlin, Germany Triple-Negative Breast Cancer (TNBC) 2018 Presentation Outline The molecular heterogeneity
More informationNational Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant
National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant Reporting Period July 1, 2012 June 30, 2013 Formula Grant Overview The National Surgical
More informationLooking Beyond the Standard-of- Care : The Clinical Trial Option
1 Looking Beyond the Standard-of- Care : The Clinical Trial Option Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor
More informationControversies in Breast Pathology ELENA PROVENZANO ADDENBROOKES HOSPITAL, CAMBRIDGE
Controversies in Breast Pathology ELENA PROVENZANO ADDENBROOKES HOSPITAL, CAMBRIDGE Neoadjuvant Chemotherapy Indications: Management of locally advanced invasive breast cancers including inflammatory breast
More informationExtended Hormonal Therapy
Extended Hormonal Therapy Dr. Caroline Lohrisch, Medical Oncologist, BC Cancer Agency Vancouver Centre November 1, 2014 www.fpon.ca Optimal Endocrine Therapy for Women with Hormone Receptor Positive Early
More informationBreast Cancer: ASCO Poster Review
Breast Cancer: ASCO Poster Review Carmen Criscitiello, MD, PhD Istituto Europeo di Oncologia Milano HER2+ SUBTYPE Research questions in early HER2+ BC De-escalation of toxicity without compromising efficacy
More informationXII Michelangelo Foundation Seminar
XII Michelangelo Foundation Seminar The opportunity of the neoadjuvant approach L. Gianni, Milan, I XII Michelangelo Foundation Seminar Milano, October 12, 2012 The opportunity of the neoadjuvant approach
More informationThe feasibility of circulating tumour DNA as an alternative to biopsy for mutational characterization in Stage III melanoma patients
The feasibility of circulating tumour DNA as an alternative to biopsy for mutational characterization in Stage III melanoma patients ASSC Scientific Meeting 13 th October 2016 Prof Andrew Barbour UQ SOM
More informationShould novel molecular therapies replace old knowledge of clinical tumor biology?
Should novel molecular therapies replace old knowledge of clinical tumor biology? Danai Daliani, M.D. Director, 1 st Oncology Clinic Euroclinic of Athens Cancer Treatments Localized disease Surgery XRT
More informationHealth Disparities Advances in Breast Cancer Treatment. Jo Anne Zujewski April 27, 2009
Health Disparities Advances in Breast Cancer Treatment Jo Anne Zujewski April 27, 2009 Disclaimer Breast Cancer Incidence 1994-2003 Breast Cancer Mortality 1994-2003 Access to Care Comorbidity Biology
More informationTriple negative breast cancer Biology and targeted therapy
Triple negative breast cancer Biology and targeted therapy MR SCI MED DR I BOŽOVIĆ -SPASOJEVIĆ INSTITUT ZA ONKOLOGIJU I RADIOLOGIJU SRBIJE I VA N A B O Z O V I C @ O U T L O O K. C O M Current challanges
More informationESMO Breast Cancer Preceptorship Singapore November Special Issues in Treatment of Young Women with Breast Cancer
ESMO Breast Cancer Preceptorship Singapore November 2017 Special Issues in Treatment of Young Women with Breast Cancer Prudence Francis MD Peter MacCallum Cancer Centre Melbourne, Australia Conflict of
More informationSystemic Therapy Considerations in Inflammatory Breast Cancer
Systemic Therapy Considerations in Inflammatory Breast Cancer Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel Disclosures Roche: Speakers bureau,
More informationSession 4 Rebecca Poulos
The Cancer Genome Atlas (TCGA) & International Cancer Genome Consortium (ICGC) Session 4 Rebecca Poulos Prince of Wales Clinical School Introductory bioinformatics for human genomics workshop, UNSW 20
More informationBiomarkers for HER2-directed Therapies : Past Failures and Future Perspectives
Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Ian Krop Dana-Farber Cancer Institute Harvard Medical School Inchon 2018 Adjuvant Trastuzumab Improves Outcomes in HER2+ Breast
More informationDiscovery Dataset. PD Liver Luminal B/ Her-2+ Letrozole. PD Supraclavicular Lymph node. PD Supraclavicular Lymph node Luminal B.
Discovery Dataset 11T pt1cpn2am1(liver) 2009 2010 Liver / Her-2+ 2011 Death Letrozole CHT pt1cpn0(sn)m0 Supraclavicular Lymph node Death 12T 2003 2006 2006 2008 Anastrozole Local RT+Examestane Fulvestrant
More informationRNA preparation from extracted paraffin cores:
Supplementary methods, Nielsen et al., A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor positive breast cancer.
More information10/15/2012. Biologic Subtypes of TNBC. Topics. Topics. Histopathology Molecular pathology Clinical relevance
Biologic Subtypes of TNBC Andrea L. Richardson M.D. Ph.D. Brigham and Women s Hospital Dana-Farber Cancer Institute Harvard Medical School Boston, MA Topics Histopathology Molecular pathology Clinical
More informationQuestion 1 A. ER-, PR-, HER+ B. ER+, PR+, HER2- C. ER-, PR+, HER2- D. ER-, PR-, HER2- E. ER-, PR+, HER2+
Triple Negative Breast Cancer Laura C. Collins, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA Question 1 The tumor depicted on the next slide
More informationEARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY. Dr. Carlos Garbino
EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY Dr. Carlos Garbino EARLY BREAST CANCER ADJUVANT CHEMOTHERAPY SUSTANTIVE DIFFICULTIES FOR A WORLDWIDE APPLICABILITY DUE TO IMPORTANT INEQUALITIES + IN DIFFERENT
More informationSYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER
SYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER Sunil Shrestha 1*, Ji Yuan Yang, Li Shuang and Deepika Dhakal Clinical School of Medicine, Yangtze University, Jingzhou, Hubei Province, PR. China Department
More informationAssessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint
Assessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint William J. Gradishar, MD Professor of Medicine Robert H. Lurie Comprehensive Cancer Center of Northwestern University Classical
More informationOutline. Outline. Phillip G. Febbo, MD. Genomic Approaches to Outcome Prediction in Prostate Cancer
Genomic Approaches to Outcome Prediction in Prostate Cancer Phillip G. Febbo, MD Duke Institute for Genome Science and Policy Department of Medicine Department of Molecular Genetics and Microbiology Duke
More informationJules Bordet Institute, Brussels, Belgium Université Libre de Bruxelles Breast International Group (BIG aisbl), Chair ESMO President
Symposium «Evaluation of the Belgian Cancer Plan» Brussels, November 26th, 2012 Personalized oncology in Europe: only a dream if national health systems do not get involved in diagnostics and pivotal cancer
More informationGenomic analysis of childhood High grade glial (HGG) brain tumors
Genomic analysis of childhood High grade glial (HGG) brain tumors Linda D Cooley Children s Mercy, Kansas City The Children s Mercy Hospital, 2017 Genomic analysis of childhood High grade glial (HGG) brain
More informationNew Developments in Cancer Treatment. Ian Rabinowitz MD
New Developments in Cancer Treatment Ian Rabinowitz MD Treatment Outline Angiogenesis inhibition Targeted therapy Immunotherapy Personalization of therapy Genomics and cancer Stem cells and cancer Angiogenesis
More informationRelevance. Axillary Node Recurrence. Purpose. Case Presentation: Is axillary staging required? Two trends have emerged:
Axillary Node Recurrence N.L. Davis Associate Professor of Surgery, UBC Head of Surgical Oncology, BCCA Relevance In an attempt to minimize long term complications and to maximize cancer control, the management
More informationMechanisms of Resistance to. Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center
Mechanisms of Resistance to Hormonal Therapy Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center Antagonizing Estrogen Dependent Growth Premenopausal
More informationPlasma-Seq conducted with blood from male individuals without cancer.
Supplementary Figures Supplementary Figure 1 Plasma-Seq conducted with blood from male individuals without cancer. Copy number patterns established from plasma samples of male individuals without cancer
More informationfor the TCGA Breast Phenotype Research Group
Decoding Breast Cancer with Quantitative Radiomics & Radiogenomics: Imaging Phenotypes in Breast Cancer Risk Assessment, Diagnosis, Prognosis, and Response to Therapy Maryellen Giger & Yuan Ji The University
More informationReview of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012
Review of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory
More informationIJC International Journal of Cancer
IJC International Journal of Cancer Short Report Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer Naama Halpern 1, Amir Sonnenblick 2,
More informationMultigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011
Multigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011 Robert W. Carlson, M.D. Professor of Medicine Stanford University Chair, NCCN Breast Cancer Treatment Guidelines Panel Selection of
More informationClaudio Zamagni Milano 16 giugno 2018 AIOM Post-ASCO BREAST CANCER HIGHLIGHTS ASCO 2018
Claudio Zamagni Milano 16 giugno 2018 AIOM Post-ASCO BREAST CANCER HIGHLIGHTS ASCO 2018 (Neo)Adjuvant Advanced De-escalation ER+ve HER2 ve Node ve TAILORx HER2 +ve Persephone PerElisa PARPi in gbrcam HER2
More informationBayesian Prediction Tree Models
Bayesian Prediction Tree Models Statistical Prediction Tree Modelling for Clinico-Genomics Clinical gene expression data - expression signatures, profiling Tree models for predictive sub-typing Combining
More informationInflammatory Breast Cancer (IBC) Epidemiology and Prognostic factors
Inflammatory Breast Cancer (IBC) Epidemiology and Prognostic factors Y.Bensouda, I.Ouziane, H.Errihani National Institute of Oncology (NIO) Rabat-Morocco Inflammatory breast cancer 1. Agressive form of
More informationJanet E. Dancey NCIC CTG NEW INVESTIGATOR CLINICAL TRIALS COURSE. August 9-12, 2011 Donald Gordon Centre, Queen s University, Kingston, Ontario
Janet E. Dancey NCIC CTG NEW INVESTIGATOR CLINICAL TRIALS COURSE August 9-12, 2011 Donald Gordon Centre, Queen s University, Kingston, Ontario Session: Correlative Studies in Phase III Trials Title: Design
More informationBreast cancer (screening) in older individuals: the oncologist s viewpoint for the geriatrician
Breast cancer (screening) in older individuals: the oncologist s viewpoint for the geriatrician Hans Wildiers Medical oncologist, Leuven, Belgium Past chairman of the EORTC elderly task force President-elect
More informationPregnancy and Breast Cancer. Elena Provenzano Addenbrookes Hospital Cambridge
Pregnancy and Breast Cancer Elena Provenzano Addenbrookes Hospital Cambridge Pregnancy and Breast Cancer Pregnancy and Breast Cancer 1. Pregnancy associated breast cancer: Histology, management, clinical
More informationSubtype-directed therapy of TNBC Global Breast Cancer Conference 2015 & 4th International Breast Cancer Symposium Jeju Island, Korea, April 2015
Subtype-directed therapy of TNBC Global Breast Cancer Conference 2015 & 4th International Breast Cancer Symposium Jeju Island, Korea, April 2015 Ruth M. O Regan, MD Visiting Professor and Division Chief
More informationRecurrence, new primary and bilateral breast cancer. José Palacios Calvo Servicio de Anatomía Patológica
Recurrence, new primary and bilateral breast cancer José Palacios Calvo Servicio de Anatomía Patológica Ipsilateral Breast Tumor Relapse (IBTR) IBTR can occur in approximately 5 20% of women after breast-conserving
More informationManagement of Inflammatory Breast Cancer: Collaboration is the path forward
Management of Inflammatory Breast Cancer: Collaboration is the path forward Massimo Cristofanilli, M.D., F.A.C.P. Professor of Medicine Associate Director of Translational Research and Precision Medicine
More informationPresent Role of Immunohistochemistry in the. Subtypes. Beppe Viale European Institute of Oncology University of Milan Milan-Italy
Present Role of Immunohistochemistry in the Classification of Molecular Subtypes Beppe Viale European Institute of Oncology University of Milan Milan-Italy We know it is many diseases Breast cancer is
More informationReliable Evaluation of Prognostic & Predictive Genomic Tests
Reliable Evaluation of Prognostic & Predictive Genomic Tests Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute http://brb.nci.nih.gov Different Kinds of Biomarkers Prognostic
More informationSession 4 Rebecca Poulos
The Cancer Genome Atlas (TCGA) & International Cancer Genome Consortium (ICGC) Session 4 Rebecca Poulos Prince of Wales Clinical School Introductory bioinformatics for human genomics workshop, UNSW 28
More informationHarmesh Naik, MD. Hope Cancer Clinic PERSONALIZED CANCER TREATMENT USING LATEST IN MOLECULAR BIOLOGY
Harmesh Naik, MD. Hope Cancer Clinic PERSONALIZED CANCER TREATMENT USING LATEST IN MOLECULAR BIOLOGY A NEW GENE A DAY.WHILE YOU ARE ENJOYING MORNING COFFEE From cancer.gov GOALS FOR THE CME TODAY A brief
More informationRisk-prediction modelling in cancer with multiple genomic data sets: a Bayesian variable selection approach
Risk-prediction modelling in cancer with multiple genomic data sets: a Bayesian variable selection approach Manuela Zucknick Division of Biostatistics, German Cancer Research Center Biometry Workshop,
More informationMalattia HER-2 positiva
Novità sul trattamento del carcinoma mammario Malattia HER-2 positiva Patrizia Vici Neoadjuvant - Adjuvant - Advanced Prognostic/Predictive factors..her-2 heterogeneity.. Neoadjuvant Phase II Pre-planned
More informationBrian T Burgess, DO, PhD, GYN Oncology Fellow Rachel W. Miller, MD, GYN Oncology
Brian T Burgess, DO, PhD, GYN Oncology Fellow Rachel W. Miller, MD, GYN Oncology Epithelial Ovarian Cancer - Standard Current Treatment: Surgery with De-bulking + Platinum-Taxane based Chemotherapy - No
More information